MEDX ... anybody following? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MEDX ... anybody following?

MEDX 31.43

-0.7%

Nov 7 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Icebrg	3/16/2007 6:58:03 PM
	of 2240

Medarex initiated with "buy" Friday, March 16, 2007 3:09:35 AM ET A.G. Edwards & Sons NEW YORK, March 16 (newratings.com) - Analysts at AG Edwards initiate coverage of Medarex Inc (MEDX.NAS) with a "buy" rating. The target price is set to $16. In a research note dated March 14 and published this morning, the analysts mention that the company’s pipeline is one of the broadest in the biotech industry. Medarex would receive royalties from BMY and PFE for ipilimumab and ticilimumab, respectively, going forward, the analysts say. The company would also receive royalties on its Phase III autoimmune candidates going ahead. The company has sufficient cash to fund its operations until 2011, AG Edwards adds. [And apart from everything else. They finally have caught up with the financial reporting].

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next